JCR Pharmaceuticals Collaborates with Acumen Pharmaceuticals to Develop Novel Alzheimer’s Therapies

Shots:JCR & Acumen have entered into a joint collaboration, option, & license agreement to develop a novel therapy to treat Alzheimer’s disease leveraging JCR’s J-Brain Cargo techAs per the deal, JCR will receive an upfront payment & an option payment if Acumen exercises its exclusive option to develop, manufacture, & commercialize up to…

ByRidhi RastogiJuly 16, 2025

NEWS

Alexion Partners with JCR Pharmaceuticals to Develop Genomic Medicines

Shots:JCR Pharmaceuticals & Alexion have entered into a license agreement for JCR’s JUST-AAV capsids to develop genomic medicinesAs per the deal, Alexion may use licensed capsids from the JUST-AAV platform in up to 5 genomic medicine programs in exchange for an undisclosed upfront payment, ~$225M in R&D milestones, ~$600M in sales milestones (milestones…

ByRidhi RastogiJuly 9, 2025

NEWS

JCR Pharmaceuticals and Modalis Progress into the Next Phase of Joint Research Agreement to Develop Gene Therapy

Shots:JCR Pharmaceuticals & Modalis have reported successful validation of initial PoC to develop gene therapy targeting CNS disease and will advance to the next phase under a new joint agreement The new agreement aims at conducting preclinical studies for gene therapy using JCR's BBB-crossing J-Brain Cargo tech and for gene therapy payload using Modalis' CRISPR-GNDM…

ByDipanshu DixitJanuary 6, 2025

TOP 20

Top 20 Cell and Gene Therapy Companies Based on 2022 Total Revenue

Shots:Standing tall and gradually paving its way through extensive research, Cell & Gene Therapy is a beacon of hope when treating rare and inherited diseases. Cell and gene therapy aims to prevent, treat, and potentially reduce the effects of the underlying cause of genetic diseases.Propelled by constant innovatory winds, the cell and gene…

ByPrince GiriMay 23, 2023

INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2023

Shots:The first quarter of 2023 highlights major acquisitions in the pharma and biotech industry along with multiple approvals. Meanwhile, Selecta and Sobi reported P-III trial (DISSOLVE I & II) results of SEL-212 for chronic refractory goutStarting with the latest acquisitions, Pfizer acquired Seagen for ~$43B. The first quarter of the year also showcases…

BySenior EditorApril 3, 2023

JCR Pharmaceuticals Collaborates with Acumen Pharmaceuticals to Develop Novel Alzheimer’s Therapies

Alexion Partners with JCR Pharmaceuticals to Develop Genomic Medicines

JCR Pharmaceuticals and Modalis Progress into the Next Phase of Joint Research Agreement to Develop Gene Therapy

Top 20 Cell and Gene Therapy Companies Based on 2022 Total Revenue

PharmaShots’ Key Highlights of First Quarter 2023

Contact US

OUR INFORMATION

FOLLOW US